On June 26, 2025, B of A Securities analyst Derik De Bruin announced an update for 10x Genomics (TXG, Financial). The analyst decided to maintain the 'Neutral' rating for the stock. This decision reflects the continued balance between potential risks and rewards for the company at this time.
In addition to maintaining the current rating, the analyst also made a notable adjustment to the stock's price target. The price target for 10x Genomics (TXG, Financial) has been raised from $12.00 to $13.00 USD. This adjustment represents an 8.33% increase in the price target, indicating a slight upward shift in the financial outlook for 10x Genomics.
10x Genomics (TXG, Financial) is listed on the NASDAQ exchange and continues to be a point of interest for investors who are observing updates from analysts like Derik De Bruin of B of A Securities.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for 10x Genomics Inc (TXG, Financial) is $13.23 with a high estimate of $18.00 and a low estimate of $10.00. The average target implies an upside of 15.15% from the current price of $11.49. More detailed estimate data can be found on the 10x Genomics Inc (TXG) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, 10x Genomics Inc's (TXG, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 10x Genomics Inc (TXG, Financial) in one year is $38.91, suggesting a upside of 238.64% from the current price of $11.49. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 10x Genomics Inc (TXG) Summary page.
